JACC. Advances · 2026
Antiplatelet Therapy in Stable Coronary Artery Disease: A Systematic Review and Meta-Analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Alzahrani Rawan Mohammed, Talmesany Terad, Alghamdi Atheer Atiah, Alhamyani Atheer Fawaz, Alghamdi Danah Abdulaziz, Alghamdi Lama Saleh, Alzahrani Miad Abdullah, Aljohani Shaima Dhaher, Alsaif Ahmed K, Azzam Ahmed Y
Аннотация
BACKGROUND: Stable coronary artery disease (CAD) affects around 200 million people worldwide. Recent evidence with P2Y12 inhibitors, direct oral anticoagulants, and combination strategies has challenged aspirin monotherapy as the standard antithrombotic approach.
OBJECTIVES: The purpose of this study was to evaluate antiplatelet strategy efficacy and safety in stable CAD, focusing on monotherapy comparisons, oral anticoagulant strategies in atrial fibrillation with CAD, intensified therapy in high-risk patients, and diabetes-specific strategies.
METHODS: We searched databases through May 13, 2025, including randomized controlled trials (RCTs) and observational studies. Primary outcomes were major adverse cardiovascular events (MACEs) and major bleeding. We performed random-effects meta-analyses, network meta-analysis, and meta-regression.
RESULTS: Twenty-three studies (437,662 patients; 13 RCTs, 6 observational, 4 post-hoc) were included. Two RCTs (HOST-EXAM, CAPRIE; n = 24,623) demonstrated clopidogrel superiority over aspirin for MACE (hazard ratio [HR] 0.73 [0.59-0.90]) and bleeding (HR 0.63 [0.41-0.97]). In atrial fibrillation with stable CAD, 2 RCTs (AFIRE, EPIC-CAD; n = 3,276) showed anticoagulant monotherapy had superior efficacy (HR 0.61 [0.49-0.76]) and safety (HR 0.52 [0.36-0.76]) vs combination therapy; observational data (Lamberts; n = 8,700) showed discordant results. Four RCTs showed intensified therapy reduced MACE (HR 0.85 [0.80-0.91]) but increased bleeding (HR 1.85 [1.65-2.07]).
CONCLUSIONS: Based on 2 RCTs, clopidogrel monotherapy may offer advantages over aspirin in stable CAD. RCT evidence supports anticoagulant monotherapy in atrial fibrillation with stable CAD beyond 12 months post-revascularization. Intensified strategies may benefit selected high-risk patients though narrow therapeutic margins (number needed to treat 91 vs number needed to harm 85) necessitate careful patient selection.
OBJECTIVES: The purpose of this study was to evaluate antiplatelet strategy efficacy and safety in stable CAD, focusing on monotherapy comparisons, oral anticoagulant strategies in atrial fibrillation with CAD, intensified therapy in high-risk patients, and diabetes-specific strategies.
METHODS: We searched databases through May 13, 2025, including randomized controlled trials (RCTs) and observational studies. Primary outcomes were major adverse cardiovascular events (MACEs) and major bleeding. We performed random-effects meta-analyses, network meta-analysis, and meta-regression.
RESULTS: Twenty-three studies (437,662 patients; 13 RCTs, 6 observational, 4 post-hoc) were included. Two RCTs (HOST-EXAM, CAPRIE; n = 24,623) demonstrated clopidogrel superiority over aspirin for MACE (hazard ratio [HR] 0.73 [0.59-0.90]) and bleeding (HR 0.63 [0.41-0.97]). In atrial fibrillation with stable CAD, 2 RCTs (AFIRE, EPIC-CAD; n = 3,276) showed anticoagulant monotherapy had superior efficacy (HR 0.61 [0.49-0.76]) and safety (HR 0.52 [0.36-0.76]) vs combination therapy; observational data (Lamberts; n = 8,700) showed discordant results. Four RCTs showed intensified therapy reduced MACE (HR 0.85 [0.80-0.91]) but increased bleeding (HR 1.85 [1.65-2.07]).
CONCLUSIONS: Based on 2 RCTs, clopidogrel monotherapy may offer advantages over aspirin in stable CAD. RCT evidence supports anticoagulant monotherapy in atrial fibrillation with stable CAD beyond 12 months post-revascularization. Intensified strategies may benefit selected high-risk patients though narrow therapeutic margins (number needed to treat 91 vs number needed to harm 85) necessitate careful patient selection.